A review on recent advancements in biologics for rheumatoid arthritis
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction. Biologic therapies targeting specific immune pathways have revolutionized RA treatment.
Objective: To provide an up-to-date comprehensive review of recent advancements in biologic agents for RA, including their mechanisms, efficacy, safety, and therapeutic positioning.
Methods: This review synthesizes current evidence from clinical trials, meta-analyses, and guidelines focusing on tumor necrosis factor inhibitors, interleukin-6 receptor antagonists, B-cell depleting agents, T-cell costimulation modulators, Janus kinase inhibitors, and emerging biologics.
Results: Biologics significantly improve disease control and slow progression. Comparative efficacy varies by agent and patient profile, with safety concerns such as infections and cardiovascular risks warranting monitoring. Biosimilars are expanding accessibility. Gaps remain in long-term safety data and personalized treatment selection.
Conclusion: Biologic therapies have transformed RA management; future research should focus on individualized strategies, long-term outcomes, and global access improvements.
Keywords:
Rheumatoid arthritis, biologic therapy, disease-modifying antirheumatic drugs, TNF inhibitors, Janus kinase inhibitors, biosimilarsDOI
https://doi.org/10.70604/References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-38.
2. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases. 2014 Jul 1;73(7):1316-22..
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25;376(9746):1094-108.
4. Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2021 Jul;73(7):1108-23.
5. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. The Journal of Rheumatology. 2006 Dec 1;33(12):2398-408.
6. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunological reviews. 2008 Jun;223(1):7-19.
7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA. 2006;295(19):2275–2285.
8. Gabay C. Interleukin-6 and chronic inflammation. Arthritis research & therapy. 2006 Jul 28;8(Suppl 2):S3.
9. Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, González-Gay MA, Mandrup-Poulsen T, Fleischmann R. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research & Therapy. 2020 Sep 9;22(1):206.
10. Navarro-Millán I, Sattui SE, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34(4):788–802.
11. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W. and Hessey, E.W., 2006. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis & Rheumatism, 54(9), pp.2793-2806.
12. Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. Journal of neurovirology. 2018 Jun;24(3):323-31.
13. Korhonen R, Moilanen E. Abatacept, a novel CD80/86–CD28 T cell co‐stimulation modulator, in the treatment of rheumatoid arthritis. Basic & clinical pharmacology & toxicology. 2009 Apr;104(4):276-84.
14. Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine. 2017 Feb 16;376(7):652-62..
15. Yates M, Mootoo A, Adas M, Bechman K, Galloway JB. Serious infection risk with JAK inhibitors compared with biologics in RA. Rheumatology (Oxford). 2021;60(1): 60–66.
16. Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, Scheinberg M, Marshall L. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Current rheumatology reports. 2017 Jun;19(6):37..
17. Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & rheumatology. 2016 Jan;68(1):1-26..
18. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of abatacept and adalimumab for RA. N Engl J Med. 2013;368(20):1972–1985.
19. Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, Zhu B, de La Torre I, De Leonardis F, Taylor PC. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. Journal of clinical medicine. 2019 Sep 5;8(9):1394.
20. Smolen JS, Landewé RB, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, De Souza S. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases. 2023 Jan 1;82(1):3-18..
21. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP, BSRBR Control Centre Consortium, BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the rheumatic diseases. 2010 Mar 1;69(3):522-8.
22. Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical therapeutics. 2012 Apr 1;34(4):788-802.
23. Van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals of the rheumatic diseases. 2013 Sep 1;72(9):1496-502.
24. Yates M, Mootoo A, Adas M, Bechman K, Galloway JB. Serious infection risk with JAK inhibitors vs biologics. Rheumatology (Oxford). 2021;60(1):60–66.
25. Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC rheumatology. 2019 Oct 22;3(1):42.
26. Singh JA. Treatment guidelines in rheumatoid arthritis. Rheumatic Disease Clinics of North America. 2022 Aug 1;48(3):679-89.
27. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis & rheumatology. 2017 Oct;69(10):1960-8..
28. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, Crossley A. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016 Sep 1;55(9):1693-7.
29. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS. Consensus-based recommendations for the use of biosimilars in RA. Ann Rheum Dis. 2018;77(2):165–174.
30. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021 Oct 23;10(11):2857.
31. Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2021 Jul;73(7):1108-23. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013 Jul 25;369(4):307-18..
32. Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH, CSP 551 RACAT Investigators*. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Annals of internal medicine. 2017 Jul 4;167(1):8-16.
33. Bykerk VP, Schoels MM. Treatment strategies for early rheumatoid arthritis. Current Opinion in Rheumatology. 2013 May 1;25(3):375-83.
34. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Jama. 2011 Apr 13;305(14):1460-8.
35. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven RV, Sharp J, Perez JL, Spencer‐Green GT. The PREMIER study: a multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2006 Jan;54(1):26-37.
36. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Annals of the rheumatic diseases. 2006 Jun 1;65(6):753-9. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomšič M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the rheumatic diseases. 2010 Jan 1;69(1):88-96.
37. Taylor PC, Alten R, Gracia JM, Kaneko Y, Walls C, Quebe A, Jia B, Bello N, Terres JR, Fleischmann R. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD open. 2022 Mar 1;8(1):e001994.
38. Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, Molenaar TE, Le Cessie S, Lems WF, van der Lubbe PA, Kerstens PJ. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Annals of internal medicine. 2016 Apr 19;164(8):523-31.
39. Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Current rheumatology reports. 2012 Oct;14(5):472-80.
40. Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD open. 2021 Feb 17;7(1).
41. Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheumatic Disease Clinics. 2012 Nov 1;38(4):727-45.
42. Chauhan K, Jandu J, Brent L, Al-Dhahir M. Rheumatoid arthritis. StatPearls. 2023 May 25.
43. Wei M, Chu CQ. Prediction of treatment response: personalized medicine in the management of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2022 Mar 1;36(1):101741.
44. Li C, Zhang Y, Song H, Gao J, Zhao DB, Zhu Q, He DY, Wang L, Li XP, Liu XD, Xiao WG. Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis. Chinese Medical Journal. 2019 Dec 20;132(24):2899-904.
45. Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, Veale DJ. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Frontiers in medicine. 2018 Aug 3;5:185.
46. Dennis Jr G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis research & therapy. 2014 Apr 30;16(2):R90.
47. Buckley, C.D., Simón-Campos, J.A., Zhdan, V., Becker, B., Davy, K., Fisheleva, E., Gupta, A., Hawkes, C., Inman, D., Layton, M. and Mitchell, N., 2020. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. The Lancet Rheumatology, 2(11), pp.e677-e688.
48. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Jama. 2011 Apr 13;305(14):1460-8.
49. Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C, Stefanelli B, Colucci F, Filippelli A. Biomarkers to personalize the treatment of rheumatoid arthritis: focus on autoantibodies and pharmacogenetics. Biomolecules. 2020 Dec 14;10(12):1672.
50. Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy. 2015 Aug 3;15(8):1107-17.
51. Heutz J, De Jong PH. Possibilities for personalised medicine in rheumatoid arthritis: hype or hope. RMD open. 2021 Oct 14;7(3).
52. Kumari A, Aggarwal G, Popli H. Precision medicine in rheumatoid arthritis: A systematic review of omics-based strategies for treatment and challenges in optimal outcomes. Molecular Medicine and Biomedical Research in the Era of Precision Medicine. 2025 Jan 1:427-47.
53. Smith MH, Berman JR. What is rheumatoid arthritis?. Jama. 2022 Mar 22;327(12):1194-1194.
54. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nature Reviews Rheumatology. 2009 Oct;5(10):554-9.
55. Mahmoud A, Elshenawy S, A. Ibrahim A, Adel Y, Khlidj Y, M. Al-Khalaileh A, M. AlBarakat M, Allam S, Abuelazm M. The safety and efficacy of otilimab for rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. The Egyptian Journal of Internal Medicine. 2025 May 30;37(1):75.
56. Mease PJ. Biologic therapy of psoriatic arthritis. InPsoriatic Arthritis and Psoriasis: Pathology and Clinical Aspects 2016 Jan 12 (pp. 295-308). Cham: Springer International Publishing..
57. Mease PJ, Deodhar AA, Van Der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Annals of the rheumatic diseases. 2022 Jun 1;81(6):815-22.
58. Westhovens R. Filgotinib in rheumatoid arthritis. Expert Review of Clinical Immunology. 2023 Feb 1;19(2):135-44.
59. Arneson LC, Carroll KJ, Ruderman EM. Brutons tyrosine kinase inhibition for the treatment of rheumatoid arthritis. ImmunoTargets and therapy. 2021 Aug 28:333-42.
60. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Jones, D.A., Musser, T.K., Grossbard, E.B. and Magilavy, D.B., 2013. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. The Journal of rheumatology, 40(4), pp.369-378..
61. Lu X, Wang X, Nian H, Yang D, Wei R. Mesenchymal stem cells for treating autoimmune dacryoadenitis. Stem Cell Research & Therapy. 2017 Jun 5;8(1):126.
62. Zhang ML, Li HB, Jin Y. Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Frontiers in Genetics. 2024 Apr 11;15:1364742.
63. Wang Q, Qin X, Fang J, Sun X. Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies. Acta Pharmaceutica Sinica B. 2021 May 1;11(5):1158-74.
64. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021 Oct 23;10(11):2857.
65. Mok CC, Van Der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clinical rheumatology. 2013 Oct;32(10):1429-35.
66. Wlassits R, Mller M, Fenzl KH, Lamprecht T, Erlacher L. JAK-Inhibitors a story of success and adverse events. Open Access Rheumatology: Research and Reviews. 2024 Dec 31:43-53.
67. Horton SC, Nam JL, Buch MH. Safety of biologics in rheumatoid arthritis. International Journal of Clinical Rheumatology. 2012 Aug 1;7(4):425.
68. Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, Giles J, Singh N. JAK inhibitors and black box warnings: what is the future for JAK inhibitors?. Expert review of clinical immunology. 2023 Nov 2;19(11):1385-97.
69. Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Biomarkers in rheumatoid arthritis. Israel Medical Association Journal. 2017;19(8):512-6.
70. Madrid-Paredes A, Martín J, Márquez A. -Omic approaches and treatment response in rheumatoid arthritis. Pharmaceutics. 2022 Aug 8;14(8):1648.
71. Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, Jacobs I. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatology international. 2016 May;36(5):613-25.
72. Sharma SD, Bluett J. Towards personalized medicine in rheumatoid arthritis. Open Access Rheumatology: Research and Reviews. 2024 Dec 31:89-114.
73. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology. 2001 Nov 1;40(11):1211-20.
74. Sandhu G, Thelma BK. New druggable targets for rheumatoid arthritis based on insights from synovial biology. Frontiers in Immunology. 2022 Feb 21;13:834247.
75. Nowell WB, Curtis JR. Remote therapeutic monitoring in rheumatic and musculoskeletal diseases: opportunities and implementation. Medical research archives. 2023 Jul;11(72):3957.
Published
Abstract Display: 75 
PDF Downloads: 18 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
.